Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
$245.20
3.74 (1.50%)
ALNY Stock Quote Delayed 30 Minutes
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
29.14B
PE Ratio
-148.61
EPS
-1.65
Volume (Avg. Vol.)
1.24M
Day's Range
$238.46 - $251.56
52-Week Range
$141.98 - $304.39
Dividend & Yield
N/A (N/A)
ALNY Stock Predictions, Articles, and Alnylam Pharmaceuticals, Inc. - Common Stock News
ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.
Why Is Alnylam (ALNY) Stock Up 50% Today?
ALNY stock is quickly moving higher as Wall Street weighs Alnylam's encouraging results for a hard-to-treat condition.
Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.
Alnylam Pharmaceuticals (ALNY) a Buy on Healthy Quant Score
Currently, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for the last month.
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough
Alnylam Pharmaceuticals (ALNY) shares skyrocketed more than 50% on Wednesday morning on the news that the company's latest drug impressed.
Is Now the Time to Buy Into These 5 Biotech ETFs?
After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out
40 Biotechnology Stocks to Sell Now
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
40 Biotechnology Stocks to Sell Now
The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
52 Biotechnology Stocks to Sell Now
The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
19 Biotechnology Stocks to Sell Now
This week, the ratings of 19 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
